scholarly journals Influenza outbreaks in nursing homes with high vaccination coverage in Navarre, Spain, 2011/12

2012 ◽  
Vol 17 (14) ◽  
Author(s):  
J Castilla ◽  
F Cía ◽  
J Zubicoa ◽  
G Reina ◽  
V Martínez-Artola ◽  
...  

In the 2011/12 season, three influenza outbreaks were studied in nursing homes with high vaccination coverage in Navarre, Spain. Attack rates ranged from 2.9% to 67%. Influenza A/Stockholm/18/2011(H3N2) virus strain was isolated from the three outbreaks. Vaccination should be complemented with other hygiene measures in nursing homes. Early detection of influenza outbreaks in nursing homes can aid in their control.

Intervirology ◽  
2003 ◽  
Vol 46 (4) ◽  
pp. 199-206 ◽  
Author(s):  
José França de Barros Jr. ◽  
Daniela Sales Alviano ◽  
Maria Helena da Silva ◽  
Marcia Dutra Wigg ◽  
Celuta Sales Alviano ◽  
...  

2002 ◽  
Vol 23 (2) ◽  
pp. 82-86 ◽  
Author(s):  
Reiko Saito ◽  
Hiroshi Suzuki ◽  
Hitoshi Oshitani ◽  
Takatsugu Sakai ◽  
Nao Seki ◽  
...  

Objective:To evaluate the effectiveness of influenza vaccines against influenza-like illness (ILI) among nursing home residents.Design:Prospective, nonrandomized, cohort study.Setting:Nine nursing homes during the 1998-1999 influenza season and 11 nursing homes during the 1999-2000 influenza season in Niigata Prefecture, Japan.Participants:Six hundred ninety-nine residents and 440 healthcare workers (HCWs) during the first season, and 930 residents and 517 HCWs during the second season, with vaccination rates ranging from 0% to 97.7%.Results:Overall, ILI decreased from 24.3% during the 1998-1999 season to 8.8% during the 1999-2000 season. Multivariate analysis adjusted for several factors, including gender, age, underlying diseases, and resident and HCW vaccination rates, failed to demonstrate clear individual protection of residents (relative risk [RR], 1.42; P = .2 for the first season; RR, 0.95; P = .9 for the second season). However, vaccination rates of 60% or greater for residents and HCWs reduced the risk of ILI, and also could prevent outbreaks during the 2 seasons. Highly impaired activities of daily living and chronic respiratory diseases were significantly associated with increased ILI.Conclusions:A high vaccination rate for both residents and HCWs may reduce the risk of ILI and institutional outbreaks in nursing homes


Author(s):  
Mei Shang ◽  
Lenee Blanton ◽  
Sonja Olsen ◽  
Alicia Fry ◽  
Lynnette Brammer

ObjectiveTo characterize and describe influenza-associated pediatric deathsin the United States over five influenza seasons, 2010–11 through2014–15.IntroductionCommunity influenza infection rates are highest among children.In children, influenza can cause severe illness and complicationsincluding, respiratory failure and death. Annual influenza vaccinationis recommended for all persons aged≥6 months. In 2004, influenza-associated deaths in children became a notifiable condition.MethodsDeaths that occurred in children aged <18 years with laboratory-confirmed influenza virus infection were reported from states andterritories to the Centers for Disease Control and Prevention on astandard case report form. We used population estimates from theU.S. Census Bureau, 2011 to 2015, to calculate age group-adjustedincidence. We used Wilcoxon-rank-sum test to compare medians andchi-square and Mantel-Haenszel chi-square to compare differencesbetween proportions of two groups.ResultsFrom October 2010 through September 2015, 590 influenza-associated pediatric deaths were reported. The median age at timeof death was 6 years (interquartile range, 1–12 years). Half of thechildren (285/572) had at least one underlying medical condition.Neurologic conditions (26%) and development delay (21%) weremost commonly reported. The average annual incidence rate was0.16 per 100,000 children (95% confidence interval [CI]: 0.15–0.17)and was highest among children aged <6 months (0.75, 95% CI,0.60–0.94 per 100,000 children), followed by children aged6–23 months (0.34, 95% CI, 0.28–0.41 per 100,000 children). Only21% (87/409) of pediatric deaths in children≥6 months had evidenceof full influenza vaccination. Vaccination coverage was lower inchildren aged 6–23 months (15%) and 5–8 years (17%) than withthose aged 2–4 years and 9–17 years (25%, p<0.01). The majorityof children aged <2 years who died had no underlying medicalconditions (63%, 105/167); this proportion was significantly higherthan that in children aged≥2 years (45%, 182/405, p<0.01).Overall 65% (383) of pediatric deaths had influenza A virusdetected, and 33% had influenza B virus detected. Children infectedwith influenza B virus had a higher frequency of sepsis/shock(41%, 72/174), acute respiratory distress syndrome (ARDS, 33%,58/174), and hemorrhagic pneumonia/pneumonitis (8%, 14/174) thanchildren infected with either influenza A(H1N1) pdm09 or influenzaA(H3N2) virus (p=0.01, 0.03, 0.03, respectively).Overall 81% (421/521) of children had an influenza-associatedcomplication; the most commonly reported were pneumonia (40%),sepsis/shock (31%) and ARDS (29%). Among those with testingreported, invasive bacteria coinfections were identified in 43%(139/322);β-hemolyticStreptococcus(20%) andStaphylococcusaureus(17%) were reported most frequently.Most children (39%, 212/548) died within 3 days of symptomonset, 28% died 4–7 days after onset, and 34% died≥8 days afteronset. The median days from illness onset to death for children withan underlying condition was significantly longer than the time forpreviously healthy children (7 versus 4 days, p<0.01).ConclusionsEach year, a substantial number of influenza-associated deathsoccur among U.S. children, with rates highest among those aged<2 years. While half of the deaths were among children withunderlying conditions, the majority of children <2 years who diedwere previously healthy. Vaccination coverage was very low.Influenza vaccination among pregnant women, young children andchildren with high-risk underlying conditions should be encouragedand could reduce influenza-associated mortality among children.


2010 ◽  
Vol 48 (4) ◽  
pp. 231-233 ◽  
Author(s):  
Martin C.W. Chan ◽  
Nelson Lee ◽  
Rity Y.K. Wong ◽  
Wing-Shan Ho ◽  
Joseph J.Y. Sung

PLoS ONE ◽  
2009 ◽  
Vol 4 (5) ◽  
pp. e5538 ◽  
Author(s):  
Rogier Bodewes ◽  
Joost H. C. M. Kreijtz ◽  
Chantal Baas ◽  
Martina M. Geelhoed-Mieras ◽  
Gerrie de Mutsert ◽  
...  

2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Christelle Elias ◽  
Anna Fournier ◽  
Anca Vasiliu ◽  
Nicolas Beix ◽  
Rémi Demillac ◽  
...  

1979 ◽  
Vol 9 (6) ◽  
pp. 688-692
Author(s):  
J A Daisy ◽  
F S Lief ◽  
H M Friedman

The efficacy for direct immunofluorescence of a commercial conjugate for influenza A virus prepared against whole A/Udorn (H3NS) virus was studied. The conjugate was specific for influenza A virus, but its sensitivity varied depending upon the strain of influenza A tested. Nasopharyngeal aspirates collected from 25 patients during an outbreak of influenza were examined for viral antigen with the conjugates and inoculated onto monkey kidney (MK) cells for virus isolation. Fifteen patients had isolates for influenza A/USSR/90/77 (H1N1); nasopharyngeal secretions were fluorescent antibody positive in 12. Fluorescent antibody was copositive with culture in 11/15 patients (73.3%) and conegative in 9/10 (90%). The one fluorescent antibody-positive, culture-negative patient had negative serology for influenza A and the fluorescent antibody result was considered to be a false positive. At a 1:10 dilution, the conjugate stained nasopharyngeal and MK cells infected with A/USSR (H1N1) 2 to 3+, whereas cells infected with H3N2 virus stained 4+. A conjugate made specifically against the ribonucleoprotein antigen, which is universal to all influenza A strains, may improve the sensitivity of the direct immunofluorescent test.


2019 ◽  
Vol 228 ◽  
pp. 26-31 ◽  
Author(s):  
Zhao Wang ◽  
Jieshi Yu ◽  
Milton Thomas ◽  
Chithra C. Sreenivasan ◽  
Ben M. Hause ◽  
...  

2014 ◽  
Vol 58 (12) ◽  
pp. 7188-7197 ◽  
Author(s):  
Alireza Eshaghi ◽  
Sarah Shalhoub ◽  
Paul Rosenfeld ◽  
Aimin Li ◽  
Rachel R. Higgins ◽  
...  

ABSTRACTImmunocompromised patients are predisposed to infections caused by influenza virus. Influenza virus may produce considerable morbidity, including protracted illness and prolonged viral shedding in these patients, thus prompting higher doses and prolonged courses of antiviral therapy. This approach may promote the emergence of resistant strains. Characterization of neuraminidase (NA) inhibitor (NAI)-resistant strains of influenza A virus is essential for documenting causes of resistance. In this study, using quantitative real-time PCR along with conventional Sanger sequencing, we identified an NAI-resistant strain of influenza A (H3N2) virus in an immunocompromised patient. In-depth analysis by deep gene sequencing revealed that various known markers of antiviral resistance, including transient R292K and Q136K substitutions and a sustained E119K (N2 numbering) substitution in the NA protein emerged during prolonged antiviral therapy. In addition, a combination of a 4-amino-acid deletion at residues 245 to 248 (Δ245-248) accompanied by the E119V substitution occurred, causing resistance to or reduced inhibition by NAIs (oseltamivir, zanamivir, and peramivir). Resistant variants within a pool of viral quasispecies arose during combined antiviral treatment. More research is needed to understand the interplay of drug resistance mutations, viral fitness, and transmission.


Sign in / Sign up

Export Citation Format

Share Document